Neurofibromatosis Type 2 Clinical Trial
Official title:
A Two-staged, Phase 2/3, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of REC-2282 in Participants With Progressive NF2 Mutated Meningiomas
This is a two-staged, Phase 2/3, randomized, multi-center study to investigate the efficacy and safety of REC-2282 in patients with progressive NF2 mutated meningiomas.
This is a two-staged, Phase 2/3, randomized, multi-center study to investigate the efficacy and safety of REC-2282 in patients with progressive NF2 mutated meningiomas, with either NF2 disease-related meningioma or recurrent sporadic meningiomas that have NF2 mutations. Cohort A will provide early data on efficacy and safety of REC-2282 in participants with progressive NF2 mutated meningiomas, and provide guidance for the dose in the confirmatory part of the study (Cohort B). The purpose of Cohort B of the study is to assess the efficacy and safety of REC-2282 compared with placebo in participants with progressive NF2 mutated meningiomas. In both cohorts, there will be a screening period of up to 8 weeks, a treatment period, a 4-week safety follow-up period after the end of treatment, and a 6-month post-study follow-up. The first 8 participants enrolled in Cohort A will complete a food effect run-in sub study. At the end of the study period, participants may be offered participation in an open-label extension (OLE) period. In Cohort A, adult participants will be randomized to one of two dose levels of REC-2282. In Cohort B, participants will be randomized to REC-2282 treatment (dose to be determined from Cohort A) arm or placebo arm in a ratio of 2:1. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05521048 -
Doxycycline in Cutaneous Schwannoma (NF2)
|
Phase 1/Phase 2 | |
| Completed |
NCT01207687 -
Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)
|
Phase 2 | |
| Completed |
NCT01767792 -
Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas
|
Phase 2 | |
| Active, not recruiting |
NCT01552434 -
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
|
Phase 1 | |
| Completed |
NCT01880749 -
Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas
|
Early Phase 1 | |
| Recruiting |
NCT04374305 -
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
|
Phase 2 | |
| Completed |
NCT01125046 -
Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
|
Phase 2 | |
| Completed |
NCT03210285 -
WES of NF2-associated in Comparison to Sporadic Vestibular Schwannomas - Correlation With Clinical Data
|
||
| Completed |
NCT02934256 -
Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
|
Phase 2 | |
| Terminated |
NCT01345136 -
Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma
|
Phase 2 | |
| Completed |
NCT02104323 -
Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
|
Phase 2 | |
| Completed |
NCT02246231 -
Effect of Implant Position on Magnetic Resonance Image Distortion
|
N/A | |
| Terminated |
NCT02282917 -
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
|
Early Phase 1 | |
| Completed |
NCT02129647 -
Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
|
Phase 2 | |
| No longer available |
NCT02589912 -
Compassionate Use Arm - ABI541 ABI for 10 NF2 Patients
|